MRK - Merck & Co., Inc.
| Previous Close | 58.64 |
| Open | 58.86 |
| Bid | 58.85 x 600 |
| Ask | 58.86 x 900 |
| Day's Range | 58.73 - 59.27 |
| 52 Week Range | 52.83 - 66.41 |
| Volume | 6,665,426 |
| Avg. Volume | 12,679,666 |
| Market Cap | 158.277B |
| Beta | 1.11 |
| PE Ratio (TTM) | 67.56 |
| EPS (TTM) | 0.87 |
| Earnings Date | May 1, 2018 |
| Forward Dividend & Yield | 1.92 (3.36%) |
| Ex-Dividend Date | 2018-03-14 |
| 1y Target Est | 66.50 |
Bloomberg Video•yesterdayUnilever Plans $7.4 Billion Buyback
Apr.19 -- Bloomberg's Heather Burke discusses Unilever strategies, m&a and the business model for advertising agencies. She speaks with Mark Barton on "Bloomberg Markets."
Yahoo Finance Video•2 days agoNEWS BITES: Barbara Bush dies at 92, Sessions proposes new limits on opioid production, tax day extended
Here’s a quick wrap up of other headlines making news today.
Yahoo Finance Video•2 days agoMARKETS: The real test for stocks is coming from the bond market
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.
- Reuters•1 hour ago
U.S. biotech companies Alnylam, Dicerna settle trade secrets case
Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.
Reuters•2 hours agoGermany's Merck seeks partners for cancer and immune system drugs
Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D. Merck has a promising drug pipeline for the first time in several years. It is looking to take a collaborative approach, as an expected decline in operating profit this year forces it to find new ways to finance pharmaceutical development.
- Zacks•3 hours ago
What's in the Cards for Glaxo (GSK) This Earnings Season?
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.
- Zacks•5 hours ago
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
- Zacks•5 hours ago
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
Markit•7 hours agoSee what the IHS Markit Score report has to say about Merck & Co Inc.
Merck & Co Inc NYSE:MRK
- TheStreet.com•8 hours ago
Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business
Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.
- The Wall Street Journal•19 hours ago
Corrections & Amplifications
Merck KGaA’s products include Femibion, a supplement for women. A Business News article in some editions Thursday about the sale of Merck KGaA’s consumer-health unit to Procter & Gamble Co. incorrectly ...
- Zacks•22 hours ago
Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer
The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.
- Reuters•22 hours ago
P&G to buy German Merck's consumer health unit for $4.2 billion
The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief. The Merck unit includes vitamin brands Femibion and Neurobion. The deal follows GlaxoSmithKline agreeing to buy Novartis out of their consumer healthcare joint venture for $13 billion after dropping its pursuit of Pfizer's consumer unit.
- TheStreet.com•yesterday
P&G Exec: The Entire Board Was Supportive of Our $4.2 Billion Deal
P&G is fresh off a big deal on Thursday. TheStreet talks with one of the company's top executives about the transaction.
- The Wall Street Journal•yesterday
[$$] P&G Needs a Workout, Not Vitamins
European dietary supplements won’t cure what ails Procter & Gamble. The consumer products maker should focus on fixing its core business to resume growth.
- Associated Press•yesterday
Procter & Gamble pays $4.2 bln for unit of Germany's Merck
FRANKFURT, Germany (AP) — German pharmaceutical and chemical company Merck says it has agreed to sell its global consumer health business to Procter & Gamble for 3.4 billion euros ($4.2 billion) in cash.
- Bloomberg•yesterday
P&G Vows More Change Coming After $4.2 Billion Acquisition
Fresh off the news of a $4.2 billion acquisition of Merck KGaA’s consumer unit, Procter & Gamble Co. reported higher sales and said more change is on the way. P&G shares declined on Thursday as investors hungry for deeper change brushed aside higher revenue in the latest quarter. It’s betting that the vitamins and decongestants obtained in the purchase of Merck’s unit will hasten its comeback.
- Bloomberg•2 days ago
P&G to Buy German Merck’s Consumer Unit for $4.2 Billion
Procter & Gamble Co. agreed to buy Merck KGaA’s consumer-health business for 3.4 billion euros ($4.2 billion) to bolster growth, betting that vitamins and decongestants can hasten its comeback. The deal gives the maker of Crest toothpaste a stable of products with sales growth of 6 percent in the past two years, double the pace of traditional consumer goods such as razors, diapers and tissues. German drugmaker Merck put the the unit up for sale last year as it pumps money into testing new medicines.
- Benzinga•2 days ago
Benzinga's Top Analyst Calls From April 18, 2018
Piper Jaffray reiterates eBay (NASDAQ: EBAY ) Overweight rating and $89 price target following news of Amazon partnership; Says it's a very smart win-win relationship and believes it will be a revenue ...
- ACCESSWIRE•2 days ago
The Newest, Undiscovered CAR-T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside Potential
- Cell therapies an emerging treatment modality, expected to blossom into $25 billion-plus industry within a decade. Manufacturing is complex, costing $50K+ per patient, and many companies turn to contract manufacturers for help with development and commercial readiness. NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Cell therapies are lined up to be one of the largest new biomedical breakthroughs in decades.
Market Realist•2 days agoAbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane
In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.
- Bloomberg•3 days ago
Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It
Hours after markets closed on Bristol-Myers Squibb Co.’s worst day in more than a year, executives used a sugary analogy to explain to Wall Street why the drugmaker’s new cancer treatment would do just ...
- Benzinga•3 days ago
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
Merck & Co., Inc. (NYSE: MRK )’s Keytruda returned better-than-expected results in the Keynote-189 lung study — a feat seen to lend a competitive edge over Bristol-Myers Squibb Co (NYSE: BMY ). The Rating ...
- Zacks•3 days ago
Merck's Keytruda Betters Survival in Lung Cancer Combo Study
Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.
- Zacks•3 days ago
Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better
Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.
